Company intelligence / Profile preview
GRO Biosciences
Cambridge, Massachusetts, United Statesgrobio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Preclinical data show promising new modalities for reversing autoimmune disease without immunosuppression and eliminating anti-drug antibodies. Lead program in refractory gout moving toward clinical trials following $60M Series B financing in July,2024.[1][2]
- Therapeutic areas
- ImmunologyEndocrinologyRheumatology
- Modalities
- Protein therapeutics (incorporating non-standard amino acids)Recombinant proteins[1][4]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Atlas Venture and Access Biotechnology are major investors/partners.Additional collaborative/partnered programs are referenced but not named specifically.[2]
Beyond the preview
Go deeper on GRO Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GRO Biosciences.